Comparative Pharmacology
Head-to-head clinical analysis: ALLEGRA HIVES versus BENADRYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLEGRA HIVES versus BENADRYL.
ALLEGRA HIVES vs BENADRYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a non-sedating antihistamine (H1-receptor antagonist) that selectively inhibits peripheral H1 receptors, reducing histamine-mediated symptoms such as pruritus, urticaria, and vasodilation. It does not cross the blood-brain barrier significantly, minimizing CNS effects.
Antihistamine; inverse agonist at histamine H1 receptors, blocking histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction; also anticholinergic and sedative.
Fexofenadine hydrochloride 60 mg orally twice daily or 180 mg orally once daily.
25-50 mg orally every 4-6 hours as needed; maximum 300 mg per day. Alternatively, 10-50 mg intramuscularly or intravenously once, maximum 100 mg per dose (IV route preferred).
None Documented
None Documented
Terminal elimination half-life is approximately 14.4 hours (range 11–17 hours). This supports once-daily dosing in most patients; however, in moderate to severe renal impairment, half-life may be prolonged (e.g., ~22 hours), necessitating dosing adjustment.
Terminal elimination half-life 4-8 hours; prolonged in hepatic impairment (up to 20 hours).
Fexofenadine is primarily excreted unchanged in feces (80%) and urine (11%). The remainder undergoes minimal hepatic metabolism. Renal elimination accounts for about 11% of the dose.
Renal (90% as metabolites, <5% unchanged); minimal biliary/fecal.
Category C
Category C
Antihistamine
Antihistamine